- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02982863
Treatment Pattern of Oral Anticoagulants (OAC) in Japan
Treatment Patterns of Newly Initiated Oral Anticoagulants on Japanese Non-valvular Atrial Fibrillation Patients Using a Japanese Claims Database
- To understand the treatment patterns of OACs and baseline patient characteristics of Japanese Non-Valvular Atrial Fibrillation (NVAF) patients
- To determine whether warfarin and dabigatran new user group can be balanced using propensity score matching using pre-specified baseline covariates.
- As an exploratory analysis, to assess mean duration of on-therapy follow-up time in database
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
-
Tokyo, Shinagawa, Japan, 1416017
- NISED Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion criteria:
- Patients aged >18 year-old with confirmed diagnosis of NVAF (ICD 10 code I48), being new starters of either dabigatran, warfarin, apixaban or edoxaban, having no prescription of other OACs for12 months prior to the index date (defined as the first prescription of OACs (the period is defined as baseline period)), and having an index date between 14 Mar 2011 to 30 June 2016
Exclusion criteria:
- Patients having less than 12 months of enrolment prior to the index date , being dialysis or kidney transplant recipients in baseline period, having either atrial flutter, valvular AF, mechanical valve placement, rheumatic AF, and/or mitral valve prolapse/regurge/stenosis in baseline period, and having record of deep vein thrombosis or pulmonary embolism < 6 months before Atrial Fibrillation (AF) diagnosis in baseline period
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: Kohort
- Tidsperspektiv: Retrospektiv
Kohorter och interventioner
Grupp / Kohort |
---|
All Patients
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Number of Patients by Each Type of Study-target OAC Drug Prescribed for New Users of Anticoagulants With NVAF
Tidsram: Day 1
|
Number of patients by each type of study-target OAC drug (dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban) prescribed as the first Oral Anticoagulants (OAC) with Non-valvular atrial fibrillation (NVAF)
|
Day 1
|
Number of Patients Prescribed OAC Drug Dabigatran by Dosage
Tidsram: Day 1
|
Number of patients prescribed OAC drug dabigatran at the index date by dosage.
If a patient had more than one prescriptions of an OAC at the day, the patient was multiple-counted.
|
Day 1
|
Number of Patients Prescribed OAC Drug Warfarin by Dosage
Tidsram: Day 1
|
Number of patients prescribed OAC drug Warfarin at the index date by dosage.
If a patient had more than one prescriptions of an OAC at the day, the patient was multiple-counted.
|
Day 1
|
Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage
Tidsram: Day 1
|
Number of patients prescribed OAC drug rivaroxaban at the index date by dosage.
If a patient had more than one prescriptions of an OAC at the day, the patient was multiple-counted.
|
Day 1
|
Number of Patients Prescribed OAC Drug Apixaban by Dosage
Tidsram: Day 1
|
Number of patients prescribed OAC drug Apixaban at the index date by dosage.
If a patient had more than one prescriptions of an OAC at the day, the patient was multiple-counted.
|
Day 1
|
Number of Patients Prescribed OAC Drug Edoxaban by Dosage
Tidsram: Day 1
|
Number of patients prescribed OAC drug edoxaban at the index date by dosage.
If a patient had more than one prescriptions of an OAC at the day, the patient was multiple-counted.
|
Day 1
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Baseline Characteristics: Age
Tidsram: 1 day
|
Baseline characteristics of patients in each treatment group: age
|
1 day
|
Baseline Characteristics: Gender
Tidsram: Day 1
|
Baseline characteristics of patients in each treatment group: gender
|
Day 1
|
Baseline Characteristics: Year of Initiating Treatment
Tidsram: Day 1
|
Baseline characteristics of patients in each treatment group: year of initiating treatment
|
Day 1
|
Baseline Characteristics: Speciality of Prescribers of OAC
Tidsram: Day 1
|
Baseline characteristics of patients in each treatment group: speciality of prescribers of OAC. int.= internal; Med.= Medicine |
Day 1
|
Baseline Characteristics: History of Disease
Tidsram: Day 1
|
Baseline characteristics of patients in each treatment group: history of disease and hospitalization.
|
Day 1
|
Baseline Characteristics: History of Hospitalization
Tidsram: Day 1
|
Baseline characteristics: history of hospitalization
|
Day 1
|
Baseline Characteristics: AF Risk Score
Tidsram: Day 1
|
Baseline characteristics of patients in each treatment group: Atrial Fibrillation (AF) risk score CHADS2: Congestive heart failure, Hypertension, Age, Diabetes, Stroke(doubled). CHADS2 score range from 0-6, with higher scores indicating the higher risk CHA2DS2VASc: Cardiac failure or dysfunction, Hypertension, Age 75 (doubled), Diabetes, Stroke (doubled) Vascular disease, Age 65-74 and Sex category (female) score. CHA2DS2VASc score range from 1-9, with higher scores indicating the higher risk. HAS-BLED: Hypertension, Abnormal renal function, Abnormal hepatic function. HAS-BLED score range from 0-8, with higher scores indicating the higher risk. |
Day 1
|
Baseline Characteristics: Concomitant Medication
Tidsram: Day 1
|
Baseline characteristics of patients in each treatment group: concomitant medication |
Day 1
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 1160-0279
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Förmaksflimmer
-
Pusan National University HospitalHar inte rekryterat ännuHjärtimplanterbar elektronisk enhet | Atrial High Rate EpisodKorea, Republiken av
-
Atrial Fibrillation NetworkDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company; Deutsches Zentrum...AvslutadAtrial High Rate EpisoderÖsterrike, Belgien, Bulgarien, Tjeckien, Frankrike, Tyskland, Grekland, Ungern, Italien, Nederländerna, Polen, Portugal, Rumänien, Spanien, Sverige, Ukraina, Storbritannien, Danmark
-
Centre Chirurgical Marie LannelongueRekryteringMedfödd hjärtsjukdom | Sinus Venosus Defekt | Sinus Venosus Atrial Septum DefektFrankrike
-
Assiut UniversityIndragenASD2 (Secundum Atrial Septal Defect)
-
Karolinska InstitutetDanderyd HospitalRekryteringFörmaksflimmer | Förmaksfladder | Supraventrikulärt slag, för tidigt | För tidiga supraventrikulära beats | För tidigt förmakskomplex | Extrasystole, AtrialSverige